Core Viewpoint - Aquestive Therapeutics Inc. is recognized as one of the top small-cap drug manufacturing stocks to consider for investment, despite a recent reduction in its price target by Alliance Global from $12 to $9 while maintaining a Buy rating [1][2]. Financial Performance - The company reported fourth-quarter revenue of $13.02 million, which fell short of consensus estimates of $13.28 million [3]. - The CEO emphasized the company's readiness to advance Anaphylm, the first oral epinephrine rescue medication, towards FDA approval by 2026 [3]. Pipeline and Product Development - The company is focused on addressing deficiencies identified by the FDA in its Complete Response Letter, with plans for NDA resubmission for Anaphylm in Q3 2026 [1][4]. - The commercial infrastructure is deemed intact and adaptable to the new timeline, with a growing allergy market and strong patient preference for Anaphylm [4]. - The company’s product offerings include Libervant, Suboxone, EMYLIF, ONDIF, SYMPAZAN, KYNMOBI, and AZSTARYS, along with proprietary pipeline items Anaphylm and AQST-108 [5]. Valuation Insights - Alliance Global provided a detailed valuation of the company's pipeline and assets, including contributions from Anaphylm and Libervant, which supports their updated view on the shares [2].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - To serve as lead plaintiff, individuals must file a motion with the court by May 4, 2026 [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been recognized as a leader in the field [4]. Group 3: Case Background - The lawsuit alleges that Aquestive made false or misleading statements regarding its New Drug Application for Anaphylm, particularly downplaying the significance of human factors in the use of its sublingual film [5].

Core Viewpoint - A class action lawsuit has been filed against Aquestive Therapeutics, Inc. for allegedly misleading investors regarding the approval status of its New Drug Application for Anaphylm, leading to significant stock price declines [2][7]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals and entities who purchased or acquired Aquestive securities between June 16, 2025, and January 8, 2026 [2]. - Investors have until May 4, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that during the class period, the defendants created a false impression that Aquestive was on track to receive approval for Anaphylm by the January 31, 2026, Prescription Drug User Fee Act (PDUFA) date [7]. - The FDA identified deficiencies in Aquestive's NDA for Anaphylm, which precluded labeling discussions and delayed the approval process [7]. - Following the announcement of these deficiencies on January 9, 2026, the stock price of Aquestive fell over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026 [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact the law firm for more details [4]. - There is no cost or obligation for investors to inquire about their rights or interests related to the lawsuit [4]. Group 4: About the Law Firm - Bragar Eagel & Squire, P.C. is a nationally recognized law firm that represents individual and institutional investors in various types of litigation [5]. - The firm has offices in New York, South Carolina, and California, and handles cases in both federal and state courts [5].

<!doctype html> <!-- For structured data --> <!-- For language declaration --> AQST DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Aquestive Therapeutics Investors of Securities Class Action Deadline on May 4, 2026 <!-- Additional Authorable Meta tags --> Accessibility StatementSkip NavigationFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) WilsonEncourages Investors Who Suffered Losses In Aquestive To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Aques ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms issuing notices may lack the necessary experience [4]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company, and has recovered hundreds of millions for investors [4]. Group 3: Class Certification Status - No class has been certified yet, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [7].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [2][5]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Aquestive and its executives failed to disclose significant deficiencies in the NDA for Anaphylm, particularly regarding human factors in the use of its sublingual film [5]. Group 2: Stock Price Impact - Following the announcement of deficiencies in the NDA by the FDA on January 9, 2026, Aquestive's stock price dropped by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share [6]. Group 3: Firm Background and Outreach - Faruqi & Faruqi, LLP has recovered hundreds of millions of dollars for investors since its founding in 1995 and has offices in multiple states [4]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding Aquestive's conduct [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The lawsuit alleges that the defendants made false or misleading statements regarding the New Drug Application for Anaphylm and concealed significant human factors related to its sublingual film [5]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements and has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Aquestive Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 4, 2026 [1]. Group 1: Class Action Details - Investors who purchased Aquestive securities between June 16, 2025, and January 8, 2026, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by May 4, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm specializes in securities class actions and has a strong track record, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked highly for its number of securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise and reputation in the field [4]. Group 3: Case Specifics - The lawsuit alleges that defendants made false or misleading statements regarding Aquestive's New Drug Application for Anaphylm, particularly downplaying the significance of human factors in the product's use [5]. - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information [5].

Core Viewpoint - Robbins LLP is urging stockholders of Aquestive Therapeutics, Inc. to participate in a class action lawsuit due to alleged misleading information regarding the approval of the drug Anaphylm [1][2]. Group 1: Class Action Details - A class action was filed on behalf of investors who purchased or acquired Aquestive Therapeutics securities between June 16, 2025, and January 8, 2026 [1]. - The allegations include that Aquestive misled investors about the approval timeline for Anaphylm, suggesting it was on track for approval by the January 31, 2026 PDUFA date, while the FDA had identified deficiencies preventing this [2][3]. Group 2: Impact on Stock Price - Following the announcement on January 9, 2026, regarding the FDA's letter identifying deficiencies, the stock price of Aquestive fell over 37%, from $6.21 per share on January 8, 2026, to $3.91 per share on January 9, 2026 [3]. Group 3: Shareholder Actions - Shareholders interested in serving as lead plaintiffs must submit their papers to the court by May 4, 2026, and can choose to remain absent class members if they do not wish to participate [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Aquestive Therapeutics, Inc. due to alleged violations of federal securities laws related to misleading statements about the company's NDA for Anaphylm [2][5]. Group 1: Legal Investigation and Class Action - The law firm is encouraging investors who suffered losses in Aquestive between June 16, 2025, and January 8, 2026, to discuss their legal rights [1]. - A federal securities class action has been filed against Aquestive, with a deadline of May 4, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest who directs the litigation on behalf of the class [7]. Group 2: Allegations Against Aquestive - The complaint alleges that Aquestive and its executives made false or misleading statements and failed to disclose critical information regarding the NDA for Anaphylm [5]. - Specifically, it is claimed that the company concealed the significance of human factors in the use of its sublingual film, including aspects like packaging and administration [5]. Group 3: Stock Price Impact - Following the announcement of deficiencies identified by the FDA in the NDA for Anaphylm, Aquestive's stock price dropped by $2.30 per share, representing a 37.04% decline, closing at $3.91 per share on January 9, 2026 [6].